Nigeria, March 25 -- Nigeria is expected to receive 179,700 doses of Lenacapavir, a newly introduced long-acting HIV prevention drug, by 2028.

The Senior Fund Portfolio Manager at the Global Fund, Jean-Thomas Noubossi, disclosed this on Tuesday during a ministerial press briefing on the commemoration of 2026 World TB Day, the Launch of the Multisectoral Accountability Framework for TB (MAF-TB) and the National Launch of Lenacapavir Pre-Exposure Prophylaxis (PrEP) for HIV prevention in Abuja.

Mr Noubossi said Nigeria is among nine early adopter nations selected for the introduction of Lenacapavir.

The initial phase will cover eight states - Anambra, Ebonyi, Kwara, Akwa Ibom, Cross River, Benue and the FCT - with the Global Fund providin...